Last reviewed · How we verify
Tulobuterol patch with placebo dry syrup
Tulobuterol is a beta-2 adrenergic agonist that stimulates beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.
Tulobuterol patch with placebo dry syrup, marketed by SamA Pharmaceutical Co., Ltd., holds a niche position in the respiratory therapy market. The drug's key strength lies in its unique delivery mechanism, which may offer improved patient compliance compared to traditional oral formulations. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Tulobuterol patch with placebo dry syrup |
|---|---|
| Sponsor | SamA Pharmaceutical Co., Ltd |
| Drug class | Beta-2 adrenergic agonist (long-acting) |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Tulobuterol activates beta-2 adrenergic receptors on bronchial smooth muscle, leading to increased intracellular cAMP and smooth muscle relaxation. This results in bronchodilation and improved airway patency. The transdermal patch formulation provides sustained systemic delivery, while the placebo dry syrup component serves as a control comparator in the marketed formulation.
Approved indications
- Asthma
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Tremor
- Headache
- Palpitations
- Nervousness
- Skin irritation at patch site
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: